Gavi's impact

In December 2021, the Gavi Board made history by approving funding to support the roll-out of the world’s first malaria vaccine – nearly 35 years in development – in sub-Saharan Africa in 2022–2025. According to the World Health Organization (WHO), the vaccine is estimated to save 1 life for every 200 children vaccinated.

Consistent funding and investment are crucial to ensure this new, vital tool reaches equally all those who need it. As long as resources are available, Gavi pledges its continued commitment and support to the fight against one of Africa’s deadliest diseases.

The issue

Children aged under five years are at the greatest risk of dying from malaria and account for more than 75% of the global deaths from the disease. Unlike adults, young children have not had the opportunity to develop partial immunity through years of exposure, making them particularly at risk.

In 2023 alone, malaria caused 597,000 deaths globally, and 432,000 child deaths in Africa – highlighting the urgent need to protect our youngest and most vulnerable. The African region shoulders the heaviest malaria burden globally, accounting for about 94% of all cases and 95% of deaths, according to WHO data.

Gavi's response

Malaria vaccines

As of October 2025, over 39 million doses have been delivered to 25 endemic countries in Africa which have introduced malaria vaccines into routine immunisation with Gavi support:

  • 7 countries have introduced the vaccine in 2025: Burundi, Uganda, Mali, Guinea, Togo, Ethiopia and Zambia; and 1 more country (Guinea-Bissau) plans to roll out the vaccine in 2025.
  • 14 countries introduced the vaccine in 2024: Cameroon, Burkina Faso, Sierra Leone, Benin, Liberia, Côte d’Ivoire, South Sudan, Mozambique, Central African Republic, Niger, Chad, Democratic Republic of the Congo, Sudan and Nigeria.
  • 3 countries – Ghana, Kenya and Malawi – introduced the first malaria vaccine, RTS,S, in 2019 during the Malaria Vaccine Implementation Programme (MVIP), co-funded by Gavi, the Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID. Since 2024, these countries have been funded under Gavi’s Malaria Vaccine Programme, aligning them with the other countries that have introduced malaria vaccines.

Malaria vaccine safety and effectiveness: Both the RTS,S/AS01 and R21/Matrix-M vaccines are prequalified and recommended by WHO to prevent malaria in children and are safe and effective.

  • In phase 3 clinical trials, both vaccines reduced malaria cases by more than half during the first year after vaccination, a period when children are at high risk of illness and death. A fourth dose given in the second year of life prolonged protection.
  • Both vaccines reduce malaria cases by 75% when given seasonally in areas of highly seasonal transmission.
  • The vaccines target P. falciparum, the deadliest malaria parasite globally and the most prevalent in Africa. More about the vaccine here: https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccinee

Useful information and resources:

Read on VaccinesWork

How to apply for vaccine support

Gavi support guidelines

Latest articles about malaria

Cabo Verde is the third African country to eliminate malaria: here’s how

Malaria in Africa accounts for 96% of deaths worldwide. Cabo Verde became only the third country in Africa to be declared malaria free this year. This is how they did it.

“Relief” as RTS,S malaria vaccine rollout set to begin in Burkina Faso

Burkina Faso suffers a “deplorable” annual death toll from malaria, with clinics and hospitals filled to overwhelm during the worst season. Health workers, parents and leaders hope that burden is about to ease.

Ultrasensitive tools ‘detect asymptomatic malaria’

Researchers have developed tools that can detect the slightest traces of malaria in people who harbour the disease but do not show signs of sickness.

Vaccine profiles: malaria

Malaria is on the rise again, fuelled by climate change, but now the world has not one but two vaccines in its arsenal to fight it.

A turning point: Cameroon rolls out world’s first malaria vaccine

Today, Cameroon makes history by launching the world’s first malaria vaccine as part of its immunisation programme – a major step in the battle against a disease that claims nearly 14,000 Cameroonian lives each year. 

Everything you need to know about the malaria vaccine

New malaria vaccines are set to revolutionise our battle against this ancient disease. Here’s everything you need to know about these lifesavers.

“The vaccine needs to be received by the greater population”: Dr Rose Leke reflects on the RTS,S roll-out

The new malaria vaccines could help bring us in sight of the end of the tunnel, says the renowned malaria scientist. But vaccine hesitancy could present a stumbling block. 

Malaria: two groundbreaking vaccines developed, now for access and rollout

The approval of two malaria vaccines – the RTS,S/AS01 vaccine in 2021 and the R21/Matrix-MTM vaccine in 2023 – will help control, and eventually help eradicate, a disease that causes more than 600,000 deaths annually, says Dr Rose Leke.

RTS,S vaccine pilot: 13% mortality reduction fuels hope for malaria control

Four years since the first children received the world’s first malaria vaccine as part of routine immunisation programmes, important questions about the real-world impact of the RTS,S/AS01 malaria vaccine are being answered.

From measles to malaria: infectious diseases that can damage your vision

The list of infectious diseases that can affect our eyesight is long, and several can lead to outright blindness. Luckily, many are preventable with vaccines.

In the dark: three blind Nigerians tell their stories

Anu Adewale, Kehinde Adegboye and Taiwo Talabi learned the hard way that vaccine-preventable diseases can rob you of your eyesight.

Last updated: 30 Oct 2025